文献速递生殖医学

辅助生殖技术治疗中卵巢刺激的最佳GnRH拮抗剂方案是什么?系统综述与网络Meta分析

What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta-analysis.
PubMed 文献 · Hum Reprod Update · 2023-01-01

该系统综述与网络Meta分析评估了不同GnRH拮抗剂方案对活产和持续妊娠的影响,检索至2021年11月23日,纳入102篇文献(对应75项独特研究),其中73项进入Meta分析。固定第5/6天方案较灵活方案持续妊娠率更高(RR 0.76,95%CI 0.62-0.94),口服避孕药预处理较无预处理持续妊娠率更低(RR 0.79,95%CI 0.69-0.92)。

要点

  • 灵活GnRH拮抗剂方案较固定第5/6天方案持续妊娠率显著降低(RR 0.76,95%CI 0.62-0.94)。
  • 口服避孕药预处理较无预处理持续妊娠率显著降低(RR 0.79,95%CI 0.69-0.92)。
  • 网络Meta分析中固定方案联合口服避孕药较固定方案无预处理持续妊娠率更低(RR 0.84,95%CI 0.71-0.99)。

核心结论

  • 现有证据大多质量与确定性低,提示不同拮抗剂方案在临床决策中不应被视为等效。
  • 需要更多试验评估加尼瑞克与西曲瑞克、不同预处理干预及灵活方案启动标准的效果。

研究设计与样本

  • 按PRISMA指南进行系统综述及直接比较的成对Meta分析,评价不同GnRH拮抗剂方案对活产和持续妊娠概率的有效性。
  • 同时进行频率学派网络Meta分析,结合直接与间接比较,以长GnRH激动剂方案为对照。
  • 检索Embase、MEDLINE、Cochrane CENTRAL、SCOPUS和Web of Science从建库至2021年11月23日。
  • 检索策略获得6738篇文献,102篇纳入系统综述(对应75项独特研究),73项纳入Meta分析。
  • 大多数研究质量低。

主要发现

  • 灵活GnRH拮抗剂方案较固定第5/6天方案持续妊娠率显著降低(RR 0.76,95%CI 0.62-0.94,I²=0%;6项RCT,n=907名参与者;低确定性证据)。
  • 口服避孕药预处理较无预处理持续妊娠率显著降低(RR 0.79,95%CI 0.69-0.92;I²=0%;5项RCT,n=1318名参与者;低确定性证据)。
  • 网络Meta分析中固定方案联合口服避孕药较固定方案无预处理持续妊娠率显著降低(RR 0.84,95%CI 0.71-0.99;中等质量证据)。
  • 累积排序曲线下面积(SUCRA)提示固定方案无预处理最可能(84%)获得最高持续妊娠率。
  • 不同预处理方案与无预处理之间、不同预处理方案之间活产率无显著差异。

关键数值与推荐

  • 灵活方案较固定第5/6天方案持续妊娠率RR 0.76(95%CI 0.62-0.94),低确定性证据。
  • 口服避孕药预处理较无预处理持续妊娠率RR 0.79(95%CI 0.69-0.92),低确定性证据。
  • 固定方案联合口服避孕药较固定方案无预处理持续妊娠率RR 0.84(95%CI 0.71-0.99),中等质量证据。
  • 固定方案无预处理SUCRA提示最可能(84%)获得最高持续妊娠率。

临床怎么用

  • 原文结论指出不同拮抗剂方案在临床决策中不应被视为等效。
  • 原文未据此给出具体推荐。

局限性

  • 大多数研究质量低。
  • 灵活方案与固定方案比较或西曲瑞克与加尼瑞克比较时缺乏活产数据。
  • 西曲瑞克与加尼瑞克比较持续妊娠率的数据不足。
  • 关于卵巢过度刺激综合征和流产率等其他结局,固定/灵活方案或口服避孕药预处理/无预处理之间证据不足。
  • 需要更多试验评估加尼瑞克与西曲瑞克、不同预处理干预及灵活方案启动标准的效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several GnRH antagonist protocols are currently used during COS in the context of ART treatments; however, questions remain regarding whether these protocols are comparable in terms of efficacy and safety. OBJECTIVE AND RATIONALE: A systematic review followed by a pairwise and network meta-analyses were performed. The systematic review and pairwise meta-analysis of direct comparative data according to the PRISMA guidelines evaluated the effectiveness of different GnRH antagonist protocols (fixed Day 5/6 versus flexible, ganirelix versus cetrorelix, with or without hormonal pretreatment) on the probability of live birth and ongoing pregnancy after COS during ART treatment. A frequentist network meta-analysis combining direct and indirect comparisons (using the long GnRH agonist protocol as the comparator) was also performed to enhance the precision of the estimates. SEARCH METHODS: The systematic literature search was performed using Embase (Ovid), MEDLINE (Ovid), Cochrane Central Register of Trials (CENTRAL), SCOPUS and Web of Science (WOS), from inception until 23 November 2021. The search terms comprised three different MeSH terms that should be present in the identified studies: GnRH antagonist; assisted reproduction treatment; randomized controlled trial (RCT). Only studies published in English were included. OUTCOMES: The search strategy resulted in 6738 individual publications, of which 102 were included in the systematic review (corresponding to 75 unique studies) and 73 were included in the meta-analysis. Most studies were of low quality. One study compared a flexible protocol with a fixed Day 5 protocol and the remaining RCTs with a fixed Day 6 protocol. There was a lack of data regarding live birth when comparing the flexible and fixed GnRH antagonist protocols or cetrorelix and ganirelix. No significant difference in live birth rate was observed between the different pretreatment regimens versus no pretreatment or between the different pretreatment protocols. A flexible GnRH antagonist protocol resulted in a significantly lower OPR compared with a fixed Day 5/6 protocol (relative risk (RR) 0.76, 95% CI 0.62 to 0.94, I2 = 0%; 6 RCTs; n = 907 participants; low certainty evidence). There were insufficient data for a comparison of cetrorelix and ganirelix for OPR. OCP pretreatment was associated with a lower OPR compared with no pretreatment intervention (RR 0.79, 95% CI 0.69 to 0.92; I2 = 0%; 5 RCTs, n = 1318 participants; low certainty evidence). Furthermore, in the network meta-analysis, a fixed protocol with OCP resulted in a significantly lower OPR than a fixed protocol with no pretreatment (RR 0.84, 95% CI 0.71 to 0.99; moderate quality evidence). The surface under the cumulative ranking (SUCRA) scores suggested that the fixed protocol with no pretreatment is the antagonist protocol most likely (84%) to result in the highest OPR. There was insufficient evidence of a difference between fixed/flexible or OCP pretreatment/no pretreatment interventions regarding other outcomes, such as ovarian hyperstimulation syndrome and miscarriage rates. WIDER IMPLICATIONS: Available evidence, mostly of low quality and certainty, suggests that different antagonist protocols should not be considered as equivalent for clinical decision-making. More trials are required to assess the comparative effectiveness of ganirelix versus cetrorelix, the effect of different pretreatment interventions (e.g. progestins or oestradiol) or the effect of different criteria for initiation of the antagonist in the flexible protocol. Furthermore, more studies are required examining the optimal GnRH antagonist protocol in women with high or low response to ovarian stimulation.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Venetis CA, Storr A, Chua SJ, et al. What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta-analysis. Hum Reprod Update. 2023. PMID: 36594696. doi:10.1093/humupd/dmac040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。